Successful re-exposure to clozapine after eosinophilia and clinically suspected myocarditis

Revista Brasileira de Psiquiatria

Volumn 35, Issue 1, 2013, Pages 95-96

  Granja Ingram, Nara Matos ^a   James, Jason ^a   Clark, Nathaniel ^a   Stovall, Jeffrey ^a   Heckers, Stephan ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE;

ADULT; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG REEXPOSURE; DYSPNEA; ELECTROCARDIOGRAPHY; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; LETTER; MALE; MYOCARDITIS; SEDIMENTATION RATE; SINUS TACHYCARDIA; T WAVE; TACHYCARDIA;

EID: 84876194600     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbp.2012.10.005     Document Type: Letter

References (5)

1. Novartis Pharmaceutical Corporation. Clozaril® (clozapine). Tablets [product monograph]. October 2011.
2. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. Clozapine-induced transient white blood count disorders. J Clin Psychiatry. 1994;55(10):429-32.
3. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458-65.
4. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry. 2010;71(8):976-81.
5. Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. Am J Psychiatry. 2006;163(2):204-8.